Warren-based Tevogen Bio Holdings recently outlined its artificial intelligence initiative, Tevogen.AI™ which aims to integrate advanced machine learning and predictive modeling into Tevogen’s proprietary ExacTcell™ technology to significantly enhance its target identification and pre-clinical processes.
Tevogen.AI currently has two proprietary technologies, each with patents pending, and an internal valuation of these assets is forthcoming.
The Company plans to expand its AI initiative with applications that extend well beyond Tevogen Bio. In preparation for this anticipated growth, Tevogen is expanding its headquarters to include dedicated facilities for Tevogen.AI’s team of data scientists and engineers.
“Health care is one of the largest segments of our economy, projected to approach $5 trillion in the U.S. in 2025 and a significant contributor to our rising national debt,” Tevogen CEO, Dr. Ryan Saadi, said. “Tevogen.AI’s vision extends beyond transforming how therapies are developed; it is expected to make a meaningful impact across multiple sectors of health care. I applaud the leadership team at Tevogen.AI and our strategic partners for their innovative efforts and contributions that will help define the future of health care.”
Tevogen currently has the following strategic partnerships:
Microsoft: Provides industry-leading AI expertise, cloud computing infrastructure (Azure), and scientific resources to accelerate drug discovery processes.
Databricks: Supplies specialized data engineering and analytics capabilities to refine Tevogen’s AI models and enhance predictive accuracy.
Proprietary Tevogen.AI Technology under PredicTcell™: AI tools capable of accurately predicting immunologically active peptide complexes and their interactions with T cell receptors, driving precision in immunotherapy treatments.
AdapTcell™: Algorithms to decode the interactions between human leukocyte antigens (HLA) and T cells.
